Pulse Biosciences Initiates Pivotal NANOPULSE-AF Clinical Study for Atrial Fibrillation Catheter
PLSE sits 82% above its 52-week low of $12.56.
Summary
Pulse Biosciences announced the enrollment of the first patients in its pivotal NANOPULSE-AF clinical study, evaluating its nPulse™ Cardiac Catheter System for treating atrial fibrillation. This marks a significant advancement in the development of its core technology.
Key Events · Product Development and Regulatory · PLSE
-
Pivotal Clinical Study Initiated
Pulse Biosciences has begun enrolling patients in its NANOPULSE-AF pivotal clinical study for the nPulse™ Cardiac Catheter System, targeting drug-resistant atrial fibrillation.
-
First Patients Enrolled
The first seven patients have been treated in the multicenter study, which plans to enroll approximately 215 participants across various clinical sites.
-
Builds on Strong Feasibility Data
This study follows a European feasibility study that demonstrated 96% procedural success at 12 months and 100% acute success, exceeding typical recurrence rates.
-
Key Product Advancement
The nPulse™ Cardiac Catheter System utilizes proprietary nanosecond pulsed field ablation (nsPFA™) energy, designed for precise lesion formation and efficient workflow in cardiac ablation.
Analysis · PLSE · Industrial Applications And Services
This 8-K reports a critical milestone for Pulse Biosciences: the initiation and first patient enrollment in its pivotal NANOPULSE-AF clinical study. This study is designed to evaluate the safety and effectiveness of the nPulse™ Cardiac Catheter System, a key product for the company, in treating recurrent atrial fibrillation. Building on strong prior feasibility data (96% procedural success at 12 months), the progression to a pivotal trial is a major step towards potential regulatory approval and commercialization. Successful outcomes in this 215-patient study would significantly de-risk the product and could be a substantial catalyst for the company's future growth. Investors should monitor the progress and future data readouts from this study.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.4% of the 1171 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLSE was trading at $22.85 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $12.56 to $26.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.